Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipopolysaccharide (LPS), also known as endotoxin, is a major structural component of the outer membrane of Gram-negative bacteria. It consists of lipid A, a core oligosaccharide, and an O-antigen. LPS is a potent immunostimulant, activating the innate immune system via TLR4. While essential for bacterial survival, LPS can induce septic shock in hosts. Lipooligosaccharides (LOS) are truncated forms lacking the O-antigen.
LPS interacts with TLR4, triggering downstream signaling cascades leading to inflammation. Drugs can neutralize LPS or block TLR4 activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide (LPS).